$SRZN

TCG Crossover GP II, LLC sold $6.9M of SRZN (indirect holdings)

TCG Crossover GP II, LLC sold 325,000 indirectly-held shares of Surrozen, Inc./DE (SRZN) at $21.25 ($6.91M total) across 2 trades on 2026-07-22.

Original reporting
SEC EDGAR · TCG Crossover GP II, LLC
Published Jul 25, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 25, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRZN
Neutral
medium confidence
Mentioned
$SRZN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRZNNeutralLow
01

Why it matters

This provides a concrete datapoint on insider selling activity (325,000 shares at $21.25) but does not include any new operational or financial information that would directly change valuation assumptions.

02

Market read

Traders may monitor for follow-on selling or correlate with other upcoming catalysts, but the filing alone is unlikely to materially move the stock.

03

What to watch

The transaction is indirect and the article lacks details on tax, hedging, or prior planned sales; without those, interpreting it as a bearish signal is speculative.

Relevance 6/10Novelty 4/10Timing: Form 4 filed 2026-07-24 for a sale executed 2026-07-22.

Background

The article is an SEC Form 4 insider transaction disclosure for Surrozen, Inc. (SRZN) by TCG Crossover GP II, LLC as a 10% owner, executed as an open-market sale.

Company-level read

Ticker impact

$SRZNNeutralMedium confidence
Context

Surrozen, Inc. disclosed a 10% owner indirect open-market sale of 325,000 shares at $21.25 on 2026-07-22 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

Form 4 shows sale size and price, but provides no earnings, guidance, or operational catalyst. Absence of a 10b5-1 plan can raise attention, yet the article contains no additional context on intent or company performance.

Market effects

No sector read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs, and the filing does not indicate any change in business outlook.

Key entities

  • Surrozen, Inc.

    Subject of the Form 4 disclosure, SRZN.

  • TCG Crossover GP II, LLC

    10% owner reporting an indirect open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRZNHighAI 8/10

Surrozen receives FDA clearance for SZN-8141 IND application

Surrozen (NASDAQ: SRZN) received FDA clearance for its SZN-8141 IND application, a treatment for diabetic macular edema. The company expects to dose the first patient in a Phase 1b/2a study in Q4 2026. The FDA clearance triggers a $95.1 million funding milestone, expected to close on October 20, 2026. Initial data from the DUET study is anticipated in H2 2027.

$SRZNMedAI 8/10

Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141…

Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The IND went into effect

$SRZNMedAI 8/10

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Surrozen (SRZN) received FDA clearance for its IND application for SZN-8141, a treatment for diabetic macular edema. The company plans to begin dosing patients in Q4 2026. This milestone triggers a $95.1M second closing of a private placement. The funds will support the development of SZN-8141 and SZN-8143, as well as broader operating activities.

$SRZNMedAI 8/10

Guggenheim Names Top Biotechnology Stock Pick

Guggenheim analyst Yatin Suneja named Surrozen Inc (SRZN) as the top biotechnology stock pick, citing progress in eye disease treatments. The company submitted an Investigational New Drug application for SZN-8141, triggering $98.4 million in funding. Guggenheim expects smooth IND clearance and clinical study initiations by late 2026. The analyst also noted upcoming Merck study results that could impact the sector.

$SRZNMed

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initia